ViiV Healthcare presents data from second Dovato (dolutegravir/lamivudine) switch study confirming non-inferior efficacy and no virologic failure versus a broad range of regimens of at least 3 drugs

ViiV Healthcare today presented 48-week data from the SALSA study at the International AIDS Society Conference 2021